MacroGenics, Inc. (MGNX)

Market Cap	109.44M -37.1%
Revenue (ttm)	127.63M -9.7%
Net Income	-75.89M
EPS	-1.21
Shares Out	63.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,143,034
Open	1.615
Previous Close	1.750
Day's Range	1.595 - 1.765
52-Week Range	0.990 - 2.785
Beta	1.48
Analysts	Hold
Price Target	3.20 (+84.97%)
Earnings Date	Mar 19, 2026

About MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 341
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX
• Website: https://www.macrogenics.com

Financial Performance

In 2024, MacroGenics's revenue was $149.96 million, an increase of 155.26% compared to the previous year's $58.75 million. Losses were -$66.97 million, 639.3% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for MGNX stock is "Hold." The 12-month stock price target is $3.2, which is an increase of 84.97% from the latest price.

Price Target

$3.2

(84.97% upside)

Analyst Consensus: Hold